Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg - Trial NCT06232239
Access comprehensive clinical trial information for NCT06232239 through Pure Global AI's free database. This Phase 1 trial is sponsored by Bio-innova Co., Ltd and is currently Not yet recruiting. The study focuses on Healthy Subjects. Target enrollment is 26 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Bio-innova Co., Ltd
Timeline & Enrollment
Phase 1
Feb 27, 2024
Apr 19, 2024
Primary Outcome
Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t),Maximal measured plasma concentration (Cmax)
Summary
The study is to compare the rate and extent of absorption of a generic formulation with that
 of a reference for mulation when given as equal labeled dose. The study will be randomized,
 open-label, single dose, two way crossover design with two-period, two-treatment and
 two-sequence under fasting condition and at least 7 days washout period between the doses.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06232239
Non-Device Trial